Mark Wright has joined Nordic Nanovector ASA as head of manufacturing to oversee the production of the company’s lead drug conjugate for the treatment of cancer. The product, Betalutin, is an antibody-radionuclide-conjugate that is being developed for non-Hodgkin lymphoma. Dr Wright previously worked for Piramal Healthcare, a contract development and manufacturing organisation, and has experience producing radio-immuno conjugates as well as antibody-drug conjugates.
Nordic Nanovector announced the appointment on 2 January 2019.
Copyright 2019 Evernow Publishing Ltd